What is it about?
Indacaterol is a novel ultra long-acting bronchodilator that can safely and effectively treat moderate to severe COPD. This paper reviewed studies with 12 weeks of treatment with Indacaterol. We examined the effectiveness of Indacaterol as a treatment considering safety, efficacy and patient perspectives.
Featured Image
Photo by Markus Winkler on Unsplash
Why is it important?
Improvements in patient compliance can vastly improve outcomes. This means a once-daily treatment can equate to an improvement in the quality of care for patients over a twice-daily regime. The 24-hour treatment effect of Indacaterol sets it apart from all other comparators as a step forward in treatment.
Perspectives
Less is more for COPD treatment. The use of Indacaterol as a first-line monotherapy can reduce the frequency of dosage for patients in addition to reducing as needed treatments. We also example the dosages trialled for the lowest dosage to reach minimal clinically important differences.
Professor Kenneth R Chapman
University of Toronto
Read the Original
This page is a summary of: Comparative efficacy of indacaterol in chronic obstructive pulmonary disease, International Journal of Chronic Obstructive Pulmonary Disease, March 2012, Taylor & Francis,
DOI: 10.2147/copd.s19805.
You can read the full text:
Contributors
The following have contributed to this page
